Skip to search formSkip to main contentSkip to account menu

EAA-090

Known as: EAA 090, Perzinfotel 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Azabicyclo CompoundsOrganophosphonates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis.
OBJECTIVE To investigate the ability of perzinfotel (an N-methyl-d-aspartate receptor antagonist) and a proprietary phospholipase… 
2011
2011
Role of GluN2A and GluN2B subunits in the formation of filopodia and secondary dendrites in cultured hippocampal neurons
GluN receptors are heteromers of obligatory GluN1 subunits and GluN2(A-D) subunits. In the present study, we addressed the… 
2010
2010
Perzinfotel and fentanyl reduce the MAC of isoflurane in dogs
A BENEFICIAL reduction in the minimum alveolar concentration (MAC) of anaesthetic required to inhibit the motor response to a… 
2010
2010
DISCOVERY AND DEVELOPMENT OF VETERINARY PHARMACEUTICALS IN TELEMETERED ANIMALS
The NMDA antagonist Perzinfotel was tested for anaesthetic sparing properties in telemetered dogs and cats when used in a pre… 
2009
2009
Prodrugs of perzinfotel with improved oral bioavailability.
Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in… 
2002
2002
EAA-090. Neuroprotectant competitive NMDA antagonist
EAA-090 is a novel squaric acid amide derivative that has been identified as a potential treatment for the ischemic brain damage… 
Highly Cited
1998
Highly Cited
1998
Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an…
The diazabicyclic amino acid phosphonate 15, [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid, was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)